However, focusing on its impact on the immune system-mediated control of colon cancer and CRC metastasis, TGFβ has been definitively identified as a driver of tumor immune escape mechanisms, and its targeted inhibition in different preclinical in vivo models successfully dampened the development and metastasis of colon cancer and increased the efficacy of adoptive NK cell therapy [131,134]. The gene discussed is TGFB1; the disease is neoplasm.